KCNH2 and familial long QT syndrome: Tables 1, 2, 3 list all hERG agonist molecules reported to date along with an indication of their molecular determinants of actions if mapped, effects on other cardiac and noncardiac ion channels, antiarrhythmic benefit against the effects of congenital and/or acquired LQTS, and associated pro‐arrhythmic risk.